Loading company…
VCGT develops gene therapies for inherited retinal diseases, including retinitis pigmentosa.
Founded in 2020 and based in Kobe, Japan, VCGT researches gene therapies for retinal degenerative diseases and related manufacturing and sales. Its work uses genome editing methods to target mutations in the rhodopsin gene. In December 2024, it raised JPY 100 million from Plus Social Investment.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in